Last updated: October 30, 2026
INCRELEX, the brand name for mecasermin, is an orphan biologic used to treat severe primary insulin-like growth factor-1 deficiency in pediatric patients. Its commercial profile is defined by a very small addressable population, high treatment value per patient, limited direct competition, and supply-chain dependence on a specialized biologic manufacturing process.
Ipsen historically commercialized INCRELEX. Eton Pharmaceuticals acquired U.S. rights from Ipsen in 2024, shifting the product from a large multinational portfolio to a specialty-pharmaceutical platform focused on rare and pediatric medicines. Product-level revenue, transaction economics, and current operating margins have not been publicly disclosed in a sufficiently detailed form to establish a precise financial forecast [1][2].
What is INCRELEX and which patients does it treat?
INCRELEX is recombinant human insulin-like growth factor-1, or rhIGF-1. FDA approved it in 2005 for the long-term treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone [3].
The drug does not replace growth hormone across the broader pediatric growth-disorder market. Its label excludes children with secondary IGF-1 deficiency caused by malnutrition, hypothyroidism, growth hormone deficiency, or chronic corticosteroid therapy.
| Attribute |
INCRELEX |
| Active ingredient |
Mecasermin |
| Modality |
Recombinant protein biologic |
| FDA approval |
2005 |
| FDA pathway |
Section 351(a) biologic license application |
| Primary indication |
Severe primary IGF-1 deficiency |
| Dosage form |
Subcutaneous injection |
| Typical dosing |
0.04 to 0.08 mg/kg twice daily |
| Original U.S. sponsor |
Tercica |
| Historical global owner |
Ipsen |
| Current U.S. rights holder |
Eton Pharmaceuticals |
| Key safety issue |
Severe hypoglycemia |
| Regulatory designation |
Orphan drug |
Treatment requires administration shortly before or after meals because of the risk of hypoglycemia. The label also warns of intracranial hypertension, lymphoid tissue hypertrophy, hypersensitivity, slipped capital femoral epiphysis, and worsening scoliosis [3].
How large is the market for INCRELEX?
The addressable market is narrow. Severe primary IGF-1 deficiency is substantially less common than conventional growth hormone deficiency, and patients are concentrated in pediatric endocrinology centers.
Demand depends on four variables:
- Diagnosis of a rare endocrine disorder.
- Confirmation that the patient meets the product label.
- Insurance approval for a high-cost orphan medicine.
- Long-term treatment persistence through the growth years.
The commercial opportunity is therefore driven more by price, duration, and patient retention than by broad volume expansion. The product can generate meaningful revenue with a small patient base, but it has limited protection against diagnosis constraints, payer restrictions, treatment discontinuation, and manufacturing interruptions.
What factors support INCRELEX demand?
INCRELEX has several commercial advantages:
- It has an FDA-approved indication with no broadly interchangeable generic product.
- The disease population has limited therapeutic alternatives.
- Treatment may continue for several years.
- Pediatric endocrinologists generally manage the relevant patient population through specialized centers.
- Orphan-drug reimbursement can support high annual treatment costs when coverage criteria are met.
Demand is constrained by injection burden, hypoglycemia monitoring, limited clinical awareness, and the requirement for specialist confirmation. Patients must also have severe primary IGF-1 deficiency rather than the much larger population of children with ordinary growth hormone deficiency.
What is the financial trajectory of INCRELEX?
Public filings do not provide a consistent, stand-alone historical revenue series for INCRELEX. Ipsen reported the product within broader specialty-care or other-product categories rather than disclosing a complete annual product-level income statement. Eton’s filings similarly provide portfolio and segment information, but do not establish a fully transparent long-term INCRELEX revenue history [1][2].
The ownership transition changes the financial profile:
| Period |
Commercial position |
Financial implication |
| 2005 to 2013 |
Commercialized by Tercica and later acquired by Ipsen |
Launch and orphan-market development |
| 2013 to 2023 |
Included in Ipsen’s specialty-care portfolio |
Mature product with limited volume expansion |
| 2024 onward |
U.S. rights transferred to Eton Pharmaceuticals |
Greater concentration of product-specific commercial risk |
For Ipsen, INCRELEX was a small product within a diversified global portfolio. For Eton, the product has greater strategic relevance because specialty products contribute a larger share of the company’s revenue base. That can produce stronger commercial focus, but it also increases exposure to a single-product event, such as a supply interruption, payer restriction, regulatory action, or loss of prescriber access.
Can INCRELEX revenue be forecast from patient volume?
Only with significant assumptions. A practical revenue model would require:
- Treated patient count.
- Average patient weight.
- Dose intensity.
- Annual treatment persistence.
- Gross-to-net discounts.
- Payer mix.
- Distributor inventory.
- Patient-assistance program costs.
- Product availability by geography.
Because these data are not reported at product level, revenue estimates based only on the number of patients or list price can materially overstate net sales. The most relevant financial indicators are Eton’s consolidated product revenue, gross margin, working-capital movements, and disclosures concerning customer concentration and inventory.
When does INCRELEX lose exclusivity?
INCRELEX’s principal regulatory exclusivity has expired. FDA granted orphan-drug designation and seven years of orphan exclusivity after approval in 2005. That period would have ended in 2012, subject to the statutory approval date and any qualifying regulatory events [3][4].
The principal protein and process patents associated with recombinant IGF-1 are also old relative to the product’s approval date. Public FDA Orange Book materials do not establish a current small-molecule patent barrier comparable to the patent estates surrounding many newer branded drugs [5].
| Exclusivity category |
Status |
| Orphan-drug exclusivity |
Expired |
| New chemical entity exclusivity |
Not applicable to a biologic protein in the small-molecule sense |
| Pediatric exclusivity |
No current material exclusivity barrier identified |
| Orange Book patent protection |
No current listed patent barrier identified in the public record |
| Biologic reference-product exclusivity |
Expired for practical purposes given the 2005 approval date |
Expiration of exclusivity does not automatically produce competition. A follow-on manufacturer still needs a valid biologics license application, manufacturing capability, clinical comparability data, commercial scale, and payer access.
Does INCRELEX face Paragraph IV challenges?
No conventional Paragraph IV risk applies in the same way as it does to an NDA product.
Paragraph IV certifications address patents listed in the FDA Orange Book for small-molecule drugs approved under the Hatch-Waxman framework. INCRELEX was approved as a biologic under the Public Health Service Act. A biosimilar applicant would generally use the Biologics Price Competition and Innovation Act pathway rather than file a standard ANDA with a Paragraph IV certification [6].
A competitor could still challenge patents through district-court litigation or other validity and infringement proceedings. The absence of a major current Orange Book patent estate reduces one litigation barrier, but it does not eliminate potential process, formulation, device, or manufacturing claims.
What biosimilar risks exist for INCRELEX?
The near-term biosimilar threat appears limited by market size and technical complexity rather than by legal exclusivity.
A biosimilar developer would need to demonstrate high similarity to mecasermin and address:
- Primary sequence and higher-order structure.
- Aggregation and impurities.
- Glycosylation and other product-quality attributes, where relevant.
- Potency and receptor-binding activity.
- Stability across the approved shelf life.
- Subcutaneous delivery performance.
- Immunogenicity.
- Commercial manufacturing economics.
The small patient population may not support the cost of developing, manufacturing, and marketing a competing product. A biosimilar could become viable if the reference product’s price and annual revenue are high enough, if the manufacturer already has an rhIGF-1 platform, or if the competitor uses the product as part of a wider endocrine portfolio.
A biosimilar would face a different market problem from a conventional generic. Pharmacy-level automatic substitution would not necessarily occur. Prescriber acceptance, specialty distribution, payer policy, and treatment continuity would influence uptake.
What formulations and manufacturing assets protect INCRELEX?
The commercial product is a sterile subcutaneous solution supplied in a multidose vial. Its manufacturing value lies less in a visible formulation patent and more in control of the biological production and quality system.
Relevant manufacturing barriers include:
- Recombinant protein expression.
- Purification and removal of process impurities.
- Control of aggregation and degradation.
- Sterile filling and vial presentation.
- Stability management.
- Validated potency assays.
- Cold-chain distribution.
- Batch-release testing.
These capabilities can create practical protection after formal patent expiry. They are not absolute barriers. A well-capitalized biologics manufacturer could replicate the process architecture or develop a comparable process, but the investment must be justified by the expected market.
What licensing and acquisition deals affect INCRELEX?
The major disclosed commercial event is the transfer of U.S. rights from Ipsen to Eton Pharmaceuticals in 2024 [1][2].
The transaction has two implications. First, Eton obtained an established orphan product without incurring the full cost and duration of original clinical development. Second, Ipsen reduced exposure to a mature, niche asset that was less central to its current growth strategy.
The transaction does not by itself extend patent or regulatory exclusivity. Its value depends on Eton’s ability to maintain supply, retain endocrinology prescribers, manage reimbursement, and expand commercial efficiency.
What is the FDA and global regulatory status of INCRELEX?
INCRELEX remains an FDA-approved biologic for its narrow pediatric indication. FDA labeling continues to emphasize dosing around meals and monitoring for hypoglycemia [3].
The product has also had a European regulatory history. European authorization was granted under the name INCRELEX, but the European marketing authorization was later withdrawn at the request of the marketing authorization holder for commercial reasons, according to European Medicines Agency records [7]. This limits the product’s geographic diversification relative to medicines with active U.S., European, and Asian commercial markets.
| Region |
Regulatory position |
| United States |
FDA-approved and commercially relevant |
| European Union |
Marketing authorization withdrawn |
| Other markets |
Country-specific availability and rights require separate verification |
Which companies are challenging INCRELEX?
No major publicly established biosimilar competitor has achieved broad commercial penetration against INCRELEX. The competitive field is indirect:
- Growth hormone products treat overlapping growth-disorder populations but are not substitutes for the labeled INCRELEX population.
- Investigational IGF-1 pathway therapies could compete if they improve dosing, safety, or convenience.
- Future mecasermin biosimilars could compete on price.
- Compounded or alternative IGF-1 products would face regulatory, quality, and reimbursement barriers.
The strongest current competitive risk is not a direct generic launch. It is payer pressure, treatment substitution outside the label, and the development of more convenient endocrine products.
How strong is the INCRELEX patent estate?
The patent estate is weak as a present-day exclusivity mechanism but meaningful as historical technical protection.
| Protection layer |
Current assessment |
| Orphan exclusivity |
Expired |
| Core composition patents |
Generally expired or aged beyond the commercial launch period |
| Orange Book listings |
No major current barrier identified |
| Formulation patents |
No publicly established dominant current barrier identified |
| Manufacturing know-how |
Potentially important and not fully visible in public filings |
| Regulatory complexity |
Moderate |
| Biosimilar development difficulty |
Moderate to high |
| Commercial barrier from market size |
High |
The product’s defensibility rests on clinical familiarity, specialist relationships, supply reliability, manufacturing know-how, and reimbursement execution rather than on a long remaining patent term.
What generic or biosimilar launch scenarios exist?
Scenario 1: No direct competitor
Eton maintains supply and payer access, while the small market discourages biosimilar investment. INCRELEX retains pricing power, but growth remains limited by the size of the diagnosed population.
Scenario 2: One biosimilar entrant
A competitor seeks a narrow share through discounts to specialty pharmacies and payers. Price erosion is likely to be more gradual than with an oral generic because physician-directed biologic switching may be required.
Scenario 3: Supply disruption
A manufacturing or quality event creates temporary shortages. The impact could be disproportionate because pediatric patients may have few practical alternatives within the label.
Scenario 4: New pathway therapy
A longer-acting IGF-1 product, oral pathway therapy, or improved growth treatment reduces injection frequency or safety monitoring. This could erode use even without direct biosimilar competition.
Key Takeaways
- INCRELEX is a mature orphan biologic for severe primary IGF-1 deficiency.
- FDA approval occurred in 2005, and orphan exclusivity expired in 2012.
- The product does not face a conventional Paragraph IV challenge because it is a biologic rather than a standard Hatch-Waxman small-molecule product.
- Current commercial protection comes mainly from clinical familiarity, manufacturing know-how, specialist distribution, and the small market size.
- Ipsen transferred U.S. rights to Eton Pharmaceuticals in 2024.
- Product-level revenue and profitability are not publicly disclosed with enough consistency to support a precise historical financial trajectory.
- Direct biosimilar competition is technically possible but commercially constrained by the limited patient population and specialized manufacturing requirements.
- The main financial risks are supply continuity, payer coverage, pediatric treatment persistence, and the arrival of a more convenient IGF-1 pathway therapy.
FAQs About INCRELEX Market and Patent Risk
Is INCRELEX still patent protected?
Its principal regulatory exclusivity has expired, and no dominant current Orange Book patent barrier is established in the public record. Manufacturing know-how and process controls may still create practical protection.
Is there a generic version of INCRELEX?
No conventional generic substitution product is established. Any direct competitor would generally need to follow a biologics or biosimilar regulatory pathway.
Can a biosimilar automatically substitute for INCRELEX?
Automatic substitution depends on FDA interchangeability status, state law, payer policy, and prescriber practice. A biosimilar approval alone does not guarantee pharmacy-level substitution.
Why is INCRELEX commercially valuable despite expired exclusivity?
The drug treats a rare condition with limited approved alternatives, and its manufacturing and clinical-use requirements raise barriers beyond the patent term.
What is the principal investment risk for the INCRELEX franchise?
The principal risk is concentration in a small, mature market. Revenue can be affected by supply interruptions, reimbursement restrictions, treatment discontinuation, and a future competing therapy without requiring a patent invalidation event.
References
- Eton Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov
- Ipsen S.A. (2024). Universal registration document and annual financial report. https://www.ipsen.com
- U.S. Food and Drug Administration. (2020). INCRELEX (mecasermin) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity database. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2020). FDA approves first interchangeable biosimilar insulin product. https://www.fda.gov
- European Medicines Agency. (n.d.). INCRELEX: EPAR and product information. https://www.ema.europa.eu
